Abstract
The Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which inaugurated a global regime of minimum intellectual property rights (IPR) standards, marked the high point in the neoliberal tide as it surged across the pharmaceutical sector. The introduction and enforcement of pharmaceutical product patents, hitherto uncommon in the Global South (and also not recognized in many developed countries), was often accompanied by the privatization or closure of state-owned drug firms and an opening-up of the drug sector to foreign investment. IPR standards have been further extended and deepened post-1995 through bilateral and regional trade agreements. While the TRIPS agreement has advantaged the interests of the multinational pharmaceutical companies (MNCs), the variable degree of implementation of this agreement in different countries reported in this volume is one factor limiting that advantage. For the contemporary movement for access to affordable medicines, however, the question is whether the weaknesses in the global IPR regime itself and the resistance described in this volume are likely to be sufficient to secure such access worldwide.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ballance, R. H., J. Pogány and H. Forstner (1992) The World’s Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy (Aldershot: Edward Elgar).
Chudnovsky, D. (1983) ‘Patents and Trademarks in Pharmaceuticals’, World Development 11, 187–93.
‘Editorial Note’ (1995) Development Dialogue 1995(1), 2–4.
Expert Working Group on Research and Development (2012) Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination: Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (Geneva: World Health Organization).
Greene, J. A. (2010) ‘When Did Medicines Become Essential?’, Bulletin of the World Health Organization 88, 483–4.
Lall, S. (1975) Major Issues in Transfer of Technology to Developing Countries: A Case Study of the Pharmaceutical Industry (New York: United Nations Conference on Trade Development Secretariat).
Murray, M., N. Gasman and G. Tomson (1995) ‘Health and Drug Policies: Making Them the Top of the Agenda: A Strategy Paper’, Development Dialogue 1995(1), 5–24.
Pogge, T. W. M., M. Rimmer and K. Rubenstein (eds) (2010) Incentives for Global Public Health: Patent Law and Access to Essential Medicines (Cambridge, UK; New York: Cambridge University Press).
Rezaie, R., A. McGahan, S. Frew, A. Daar and P. Singer (2012) ‘Emergence of Biopharmaceutical Innovators in China, India, Brazil, and South Africa as Global Competitors and Collaborators’, Health Research Policy and Systems 10(1), 18.
Silver, G. A. (1998) ‘International Health Services Need an Interorganizational Policy’, American Journal of Public Health 88, 727–9.
World Trade Organization (2012) ‘The Doha Declaration Explained’, http://www.wto. org/english/tratop_e/dda_e/dohaexplained_e.htm, date accessed 25 April 2012.
Editor information
Editors and Affiliations
Copyright information
© 2013 Hans Löfgren and Owain David Williams
About this chapter
Cite this chapter
Löfgren, H., Williams, O.D. (2013). Conclusion: TRIPS, Drug Production in the Global South and Access to Medicines. In: Löfgren, H., Williams, O.D. (eds) The New Political Economy of Pharmaceuticals. International Political Economy Series. Palgrave Macmillan, London. https://doi.org/10.1057/9781137315854_13
Download citation
DOI: https://doi.org/10.1057/9781137315854_13
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-32976-2
Online ISBN: 978-1-137-31585-4
eBook Packages: Palgrave Social Sciences CollectionSocial Sciences (R0)